<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36032086</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes.</ArticleTitle><Pagination><StartPage>945021</StartPage><MedlinePgn>945021</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">945021</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.945021</ELocationID><Abstract><AbstractText>Autoantibodies to multiple targets are found during acute COVID-19. Whether all, or some, persist after 6 months, and their correlation with sustained anti-SARS-CoV-2 immunity, is still controversial. Herein, we measured antibodies to multiple SARS-CoV-2 antigens (Wuhan-Hu-1 nucleoprotein (NP), whole spike (S), spike subunits (S1, S2 and receptor binding domain (RBD)) and Omicron spike) and 102 human proteins with known autoimmune associations, in plasma from healthcare workers 8 months post-exposure to SARS-CoV-2 (n=31 with confirmed COVID-19 disease and n=21 uninfected controls (PCR and anti-SARS-CoV-2 negative) at baseline). IgG antibody responses to SARS-CoV-2 antigens were significantly higher in the convalescent cohort than the healthy cohort, highlighting lasting antibody responses up to 8 months post-infection. These were also shown to be cross-reactive to the Omicron variant spike protein at a similar level to lasting anti-RBD antibodies (correlation r=0.89). Individuals post COVID-19 infection recognised a common set of autoantigens, specific to this group in comparison to the healthy controls. Moreover, the long-term level of anti-Spike IgG was associated with the breadth of autoreactivity post-COVID-19. There were further moderate positive correlations between anti-SARS-CoV-2 responses and 11 specific autoantigens. The most commonly recognised autoantigens were found in the COVID-19 convalescent cohort. Although there was no overall correlation in self-reported symptom severity and anti-SARS-CoV-2 antibody levels, anti-calprotectin antibodies were associated with return to healthy normal life 8 months post infection. Calprotectin was also the most common target for autoantibodies, recognized by 22.6% of the overall convalescent cohort. Future studies may address whether, counter-intuitively, such autoantibodies may play a protective role in the pathology of long-COVID-19.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Moody, Sonda, Johnston, Smith, Stephens, McPherson, Flanagan and Plebanski.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moody</LastName><ForeName>Rhiane</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Health and Biomedical Science, STEM College, RMIT University, Bundoora, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonda</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Tasmanian Vaccine Trial Centre, Clifford Craig Foundation, Launceston General Hospital, Launceston, TAS, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Health Sciences and School of Medicine, University of Tasmania, Launceston, TAS, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Fay H</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>Public Health Services, Department of Health, Tasmania, TAS, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Kylie J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Public Health Services, Department of Health, Tasmania, TAS, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephens</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Tasmanian School of Medicine, University of Tasmania, Hobart, TAS, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McPherson</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tasmanian School of Medicine, University of Tasmania, Hobart, TAS, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flanagan</LastName><ForeName>Katie L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>School of Health and Biomedical Science, STEM College, RMIT University, Bundoora, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tasmanian Vaccine Trial Centre, Clifford Craig Foundation, Launceston General Hospital, Launceston, TAS, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Health Sciences and School of Medicine, University of Tasmania, Launceston, TAS, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plebanski</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Health and Biomedical Science, STEM College, RMIT University, Bundoora, VIC, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039841">Leukocyte L1 Antigen Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039841" MajorTopicYN="N">Leukocyte L1 Antigen Complex</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>29</Day><Hour>4</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36032086</ArticleId><ArticleId IdType="pmc">PMC9403331</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.945021</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in wuhan, China. Lancet (2020) 395(10223):497&#x2013;. doi:&#xa0;10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H, Xie L, Liu R, Yang J, Liu F, Wu K, et al. . Analysis of heart injury laboratory parameters in 273 covid-19 patients in one hospital in wuhan, China. J Med Virol (2020) 92(7):819&#x2013;23. doi:&#xa0;10.1002/jmv.25809</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25809</ArticleId><ArticleId IdType="pmc">PMC7228305</ArticleId><ArticleId IdType="pubmed">32232979</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalleballe K, Reddy Onteddu S, Sharma R, Dandu V, Brown A, Jasti M, et al. . Spectrum of neuropsychiatric manifestations in covid-19. Brain Behav Immun (2020) 88:71&#x2013;4. doi:&#xa0;10.1016/j.bbi.2020.06.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.06.020</ArticleId><ArticleId IdType="pmc">PMC7297688</ArticleId><ArticleId IdType="pubmed">32561222</ArticleId></ArticleIdList></Reference><Reference><Citation>Moody R, Wilson K, Flanagan KL, Jaworowski A, Plebanski M. Adaptive immunity and the risk of autoreactivity in covid-19. Int J Mol Sci (2021) 22(16):8965. doi:&#xa0;10.3390/ijms22168965</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168965</ArticleId><ArticleId IdType="pmc">PMC8396528</ArticleId><ArticleId IdType="pubmed">34445670</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas M, Rodr&#xed;guez Y, Acosta-Ampudia Y, Monsalve DM, Zhu C, Li Q-Z, et al. . Autoimmunity is a hallmark of post-covid syndrome. J Trans Med (2022) 20(1):129. doi:&#xa0;10.1186/s12967-022-03328-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03328-4</ArticleId><ArticleId IdType="pmc">PMC8924736</ArticleId><ArticleId IdType="pubmed">35296346</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodr&#xed;guez Y, Zapata E, Ram&#xed;rez-Santana C, et al. . Persistent autoimmune activation and proinflammatory state in post-coronavirus disease 2019 syndrome. J Infect Dis (2022) 225:2155&#x2013;62. doi:&#xa0;10.1093/infdis/jiac017</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac017</ArticleId><ArticleId IdType="pmc">PMC8903340</ArticleId><ArticleId IdType="pubmed">35079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, F&#xfc;rst J, Schulze-Rothe S, Wallukat A, et al. . Functional autoantibodies against G-protein coupled receptors in patients with persistent long-Covid-19 symptoms. J Transl Autoimmun (2021) 4:100100&#x2013;. doi:&#xa0;10.1016/j.jtauto.2021.100100</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. . Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (Covid-19): A prospective cohort study. Clin Infect Dis (2021) 74(7):1191&#x2013;8. doi:&#xa0;10.1093/cid/ciab611</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Masi&#xe1; M, Fern&#xe1;ndez-Gonz&#xe1;lez M, Telenti G, Agull&#xf3; V, Garc&#xed;a JA, Padilla S, et al. . Durable antibody response one year after hospitalization for covid-19: A longitudinal cohort study. J Autoimmun (2021) 123:102703&#x2013;. doi:&#xa0;10.1016/j.jaut.2021.102703</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102703</ArticleId><ArticleId IdType="pmc">PMC8289631</ArticleId><ArticleId IdType="pubmed">34303083</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Yu D, Wu X, Liang H, Zhou Z, Xie Y, et al. . Twelve-month specific igg response to sars-Cov-2 receptor-binding domain among covid-19 convalescent plasma donors in wuhan. Nat Commun (2021) 12(1):4144&#x2013;. doi:&#xa0;10.1038/s41467-021-24230-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24230-5</ArticleId><ArticleId IdType="pmc">PMC8260809</ArticleId><ArticleId IdType="pubmed">34230476</ArticleId></ArticleIdList></Reference><Reference><Citation>De Giorgi V, West KA, Henning AN, Chen LN, Holbrook MR, Gross R, et al. . Naturally acquired sars-Cov-2 immunity persists for up to 11 months following infection. J Infect Dis (2021) 224(8):1294&#x2013;304. doi:&#xa0;10.1093/infdis/jiab295</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab295</ArticleId><ArticleId IdType="pmc">PMC8195007</ArticleId><ArticleId IdType="pubmed">34089610</ArticleId></ArticleIdList></Reference><Reference><Citation>Choe PG, Kang CK, Kim K-H, Yi J, Kim ES, Park SW, et al. . Persistence of neutralizing antibody response up to 1 year after asymptomatic or symptomatic sars-Cov-2 infection. J Infect Dis (2021) 224(6):1097&#x2013;9. doi:&#xa0;10.1093/infdis/jiab339</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab339</ArticleId><ArticleId IdType="pubmed">34166506</ArticleId></ArticleIdList></Reference><Reference><Citation>Pl&#x16b;me J, Galvanovskis A, &#x160;mite S, Romanchikova N, Zayakin P, Lin&#x113; A. Early and strong antibody responses to sars-Cov-2 predict disease severity in covid-19 patients. J Trans Med (2022) 20(1):176. doi:&#xa0;10.1186/s12967-022-03382-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03382-y</ArticleId><ArticleId IdType="pmc">PMC9012069</ArticleId><ArticleId IdType="pubmed">35428263</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen-Contant P, Embong AK, Kanagaiah P, Chaves FA, Yang H, Branche AR, et al. . S protein-reactive igg and memory b cell production after human sars-Cov-2 infection includes broad reactivity to the S2 subunit. mBio (2020) 11(5):e01991&#x2013;20. doi:&#xa0;10.1128/mBio.01991-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01991-20</ArticleId><ArticleId IdType="pmc">PMC7520599</ArticleId><ArticleId IdType="pubmed">32978311</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, et al. . Magnitude and kinetics of anti&#x2013;severe acute respiratory syndrome coronavirus 2 antibody responses and their relationship to disease severity. Clin Infect Dis (2021) 72(2):301&#x2013;8. doi:&#xa0;10.1093/cid/ciaa979</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa979</ArticleId><ArticleId IdType="pmc">PMC7454426</ArticleId><ArticleId IdType="pubmed">33501951</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan FJ, Hope CM, Masavuli MG, Lynn MA, Mekonnen ZA, Yeow AEL, et al. . Long-term perturbation of the peripheral immune system months after sars-Cov-2 infection. BMC Med (2022) 20(1):26. doi:&#xa0;10.1186/s12916-021-02228-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02228-6</ArticleId><ArticleId IdType="pmc">PMC8758383</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. . Immunological memory to sars-Cov-2 assessed for up to 8 months after infection. Science (2021) 371(6529):eabf4063. doi:&#xa0;10.1126/science.abf4063</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4063</ArticleId><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Horton DB, Barrett ES, Roy J, Gennaro ML, Andrews T, Greenberg P, et al. . Determinants and dynamics of sars-Cov-2 infection in a diverse population: 6-month evaluation of a prospective cohort study. J Infect Dis (2021) 224(8):1345&#x2013;56. doi:&#xa0;10.1093/infdis/jiab411</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab411</ArticleId><ArticleId IdType="pmc">PMC8436370</ArticleId><ArticleId IdType="pubmed">34387310</ArticleId></ArticleIdList></Reference><Reference><Citation>Marklund E, Leach S, Axelsson H, Nystr&#xf6;m K, Norder H, Bemark M, et al. . Serum-igg responses to sars-Cov-2 after mild and severe covid-19 infection and analysis of igg non-responders. PLoS One (2020) 15(10):e0241104&#x2013;e. doi:&#xa0;10.1371/journal.pone.0241104</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0241104</ArticleId><ArticleId IdType="pmc">PMC7577439</ArticleId><ArticleId IdType="pubmed">33085715</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozgocer T, Dagli &#x15e;N, Ceylan MR, Disli F, Ucar C, Yildiz S. Analysis of long-term antibody response in covid-19 patients by symptoms grade, gender, age, bmi, and medication. J Med Virol (2022) 94(4):1412&#x2013;8. doi:&#xa0;10.1002/jmv.27452</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27452</ArticleId><ArticleId IdType="pmc">PMC8662095</ArticleId><ArticleId IdType="pubmed">34766646</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, Iyer NS, Munter SE, Nixon CC, et al. . Long-term sars-Cov-2-Specific immune and inflammatory responses in individuals recovering from covid-19 with and without post-acute symptoms. Cell Rep (2021) 36(6):109518&#x2013;. doi:&#xa0;10.1016/j.celrep.2021.109518</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Hojjat Jodaylami M, Dja&#xef;leb A, Ricard P, Lavall&#xe9;e &#xc9;, Cellier-Goetghebeur S, Parker M-F, et al. . Cross-reactivity of antibodies from non-hospitalized covid-19 positive individuals against the native, B.1.351, B.1.617.2 and P.1 sars-Cov-2 spike proteins. Sci Rep (2021) 11(1):21601. doi:&#xa0;10.1038/s41598-021-00844-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-00844-z</ArticleId><ArticleId IdType="pmc">PMC8575961</ArticleId><ArticleId IdType="pubmed">34750399</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurie MT, Liu J, Sunshine S, Peng J, Black D, Mitchell AM, et al. . Sars-Cov-2 variant exposures elicit antibody responses with differential cross-neutralization of established and emerging strains including delta and omicron. J Infect Dis (2022) 225:jiab635. doi:&#xa0;10.1093/infdis/jiab635</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab635</ArticleId><ArticleId IdType="pmc">PMC8755395</ArticleId><ArticleId IdType="pubmed">34979030</ArticleId></ArticleIdList></Reference><Reference><Citation>Faustini S, Shields A, Banham G, Wall N, Al-Taei S, Tanner C, et al. . Cross reactivity of spike glycoprotein induced antibody against delta and omicron variants before and after third sars-Cov-2 vaccine dose in healthy and immunocompromised individuals. J Infect (2022) 84(4):579&#x2013;613. doi:&#xa0;10.1016/j.jinf.2022.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.01.002</ArticleId><ArticleId IdType="pmc">PMC8743815</ArticleId><ArticleId IdType="pubmed">35016901</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Han T, Chen J, Hou C, Hua L, He S, et al. . Clinical and autoimmune characteristics of severe and critical cases of covid-19. Clin Trans Sci (2020) 13(6):1077&#x2013;86. doi:&#xa0;10.1111/cts.12805</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12805</ArticleId><ArticleId IdType="pmc">PMC7264560</ArticleId><ArticleId IdType="pubmed">32315487</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachoyiannopoulos PG, Magira E, Alexopoulos H, Jahaj E, Theophilopoulou K, Kotanidou A, et al. . Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with covid-19. Ann Rheum Dis (2020) 79(12):1661. doi:&#xa0;10.1136/annrheumdis-2020-218009</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218009</ArticleId><ArticleId IdType="pubmed">32581086</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al. . Autoantibodies against type I ifns in patients with life-threatening covid-19. Science (2020) 370(6515):eabd4585. doi:&#xa0;10.1126/science.abd4585</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. . Diverse functional autoantibodies in patients with covid-19. Nature (2021) 595(7866):283&#x2013;8. doi:&#xa0;10.1038/s41586-021-03631-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Ebinger JE, Mostafa R, Budde P, Gajewski J, Walker B, et al. . Paradoxical sex-specific patterns of autoantibody response to sars-Cov-2 infection. J Trans Med (2021) 19(1):524. doi:&#xa0;10.1186/s12967-021-03184-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-021-03184-8</ArticleId><ArticleId IdType="pmc">PMC8716184</ArticleId><ArticleId IdType="pubmed">34965855</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. . New-onset igg autoantibodies in hospitalized patients with covid-19. Nat Commun (2021) 12(1):5417. doi:&#xa0;10.1038/s41467-021-25509-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston F, Anderson T, Harlock M, Castree N, Parry L, Marfori T, et al. . Lessons learnt from the first Large outbreak of covid-19 in health-care settings in Tasmania, Australia. Western Pac Surveill Response J (2021) 12(4):1&#x2013;7. doi:&#xa0;10.5365/wpsar.2021.12.4.884</Citation><ArticleIdList><ArticleId IdType="doi">10.5365/wpsar.2021.12.4.884</ArticleId><ArticleId IdType="pmc">PMC8873910</ArticleId><ArticleId IdType="pubmed">35251738</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong E, Du H LF. An interactive web-based dashboard to track covid-19 in real time. Lancet Inf Dis (2020) 20(5):533&#x2013;4. doi:&#xa0;10.1016/S1473-3099(20)30120-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30120-1</ArticleId><ArticleId IdType="pmc">PMC7159018</ArticleId><ArticleId IdType="pubmed">32087114</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: What do we know about omicron sublineages? BMJ (2022) 376:o358. doi:&#xa0;10.1136/bmj.o358</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o358</ArticleId><ArticleId IdType="pubmed">35149516</ArticleId></ArticleIdList></Reference><Reference><Citation>Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. Viruses and autoimmunity: A review on the potential interaction and molecular mechanisms. Viruses (2019) 11(8):762. doi:&#xa0;10.3390/v11080762</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11080762</ArticleId><ArticleId IdType="pmc">PMC6723519</ArticleId><ArticleId IdType="pubmed">31430946</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. . Evolution of antibody immunity to sars-Cov-2. Nature (2021) 591(7851):639&#x2013;44. doi:&#xa0;10.1038/s41586-021-03207-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Siracusano G, Brombin C, Pastori C, Cugnata F, Noviello M, Tassi E, et al. . Profiling antibody response patterns in covid-19: Spike S1-reactive iga signature in the evolution of sars-Cov-2 infection.Front Immunol (2021) 12:772239. doi:&#xa0;10.3389/fimmu.2021.772239</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.772239</ArticleId><ArticleId IdType="pmc">PMC8595940</ArticleId><ArticleId IdType="pubmed">34804064</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Xu K, Li C, Zhou L, Kong X, Peng J, et al. . Long-term kinetics of sars-Cov-2 antibodies and impact of inactivated vaccine on sars-Cov-2 antibodies based on a covid-19 patients cohort. Front Immunol (2022) 13:829665. doi:&#xa0;10.3389/fimmu.2022.829665</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.829665</ArticleId><ArticleId IdType="pmc">PMC8828498</ArticleId><ArticleId IdType="pubmed">35154152</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO . Who coronavirus disease (Covid-19) dashboard: World health organisation (2020). Available at: https://covid19.who.int/.</Citation></Reference><Reference><Citation>Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. . Mrna-based covid-19 vaccine boosters induce neutralizing immunity against sars-Cov-2 omicron variant. Cell (2022) 185(3):457&#x2013;66.e4. doi:&#xa0;10.1016/j.cell.2021.12.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.033</ArticleId><ArticleId IdType="pmc">PMC8733787</ArticleId><ArticleId IdType="pubmed">34995482</ArticleId></ArticleIdList></Reference><Reference><Citation>Slight-Webb S, Lu R, Ritterhouse LL, Munroe ME, Maecker HT, Fathman CG, et al. . Autoantibody-positive healthy individuals display unique immune profiles that may regulate autoimmunity. Arthritis Rheumatol (2016) 68(10):2492&#x2013;502. doi:&#xa0;10.1002/art.39706</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39706</ArticleId><ArticleId IdType="pmc">PMC5042816</ArticleId><ArticleId IdType="pubmed">27059145</ArticleId></ArticleIdList></Reference><Reference><Citation>Neiman M, Hellstr&#xf6;m C, Just D, Mattsson C, Fagerberg L, Schuppe-Koistinen I, et al. . Individual and stable autoantibody repertoires in healthy individuals. Autoimmunity (2019) 52(1):1&#x2013;11. doi:&#xa0;10.1080/08916934.2019.1581774</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916934.2019.1581774</ArticleId><ArticleId IdType="pubmed">30835561</ArticleId></ArticleIdList></Reference><Reference><Citation>Shome M, Chung Y, Chavan R, Park JG, Qiu J, LaBaer J. Serum autoantibodyome reveals that healthy individuals share common autoantibodies. Cell Rep (2022) 39(9):110873. doi:&#xa0;10.1016/j.celrep.2022.110873</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110873</ArticleId><ArticleId IdType="pmc">PMC9221390</ArticleId><ArticleId IdType="pubmed">35649350</ArticleId></ArticleIdList></Reference><Reference><Citation>Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. Calprotectin: From biomarker to biological function. Gut (2021) 70(10):1978. doi:&#xa0;10.1136/gutjnl-2021-324855</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324855</ArticleId><ArticleId IdType="pmc">PMC8458070</ArticleId><ArticleId IdType="pubmed">34145045</ArticleId></ArticleIdList></Reference><Reference><Citation>Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflammatory Bowel Dis (2006) 12(6):524&#x2013;34. doi:&#xa0;10.1097/00054725-200606000-00013</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00054725-200606000-00013</ArticleId><ArticleId IdType="pubmed">16775498</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarlborg M, Courvoisier DS, Lamacchia C, Martinez Prat L, Mahler M, Bentow C, et al. . Serum calprotectin: A promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther (2020) 22(1):105. doi:&#xa0;10.1186/s13075-020-02190-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-020-02190-3</ArticleId><ArticleId IdType="pmc">PMC7201559</ArticleId><ArticleId IdType="pubmed">32375861</ArticleId></ArticleIdList></Reference><Reference><Citation>Stascheit F, Hotter B, Hoffmann S, Kohler S, Lehnerer S, Sputtek A, et al. . Calprotectin as potential novel biomarker in myasthenia gravis. J Transl Autoimmun (2021) 4:100111&#x2013;. doi:&#xa0;10.1016/j.jtauto.2021.100111</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100111</ArticleId><ArticleId IdType="pmc">PMC8379505</ArticleId><ArticleId IdType="pubmed">34458711</ArticleId></ArticleIdList></Reference><Reference><Citation>Shokri-Afra H, Alikhani A, Moradipoodeh B, Noorbakhsh F, Fakheri H, Moradi-Sardareh H. Elevated fecal and serum calprotectin in covid-19 are not consistent with gastrointestinal symptoms. Sci Rep (2021) 11(1):22001. doi:&#xa0;10.1038/s41598-021-01231-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-01231-4</ArticleId><ArticleId IdType="pmc">PMC8578669</ArticleId><ArticleId IdType="pubmed">34753964</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahler M, Meroni P-L, Infantino M, Buhler KA, Fritzler MJ. Circulating calprotectin as a biomarker of covid-19 severity. Expert Rev Clin Immunol (2021) 17(5):431&#x2013;43. doi:&#xa0;10.1080/1744666X.2021.1905526</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2021.1905526</ArticleId><ArticleId IdType="pmc">PMC8054493</ArticleId><ArticleId IdType="pubmed">33750254</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>